A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LP-108, a BCL-2 Inhibitor, Combined With Azacitidine In Subjects With AML, MDS, CMML

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05641259
• Other study ID #: LP-108-CN102
• Status: Recruiting
• Phase: Phase 1
• Start date: February 14, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: February 2024
• Source: Guangzhou Lupeng Pharmaceutical Company LTD.
• Contact: Yue Shen, PhD
• Phone: 86-020-31605119
• Email: yshen[@]lupengbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label, multicenter, dose-escalation & expansion study to evaluate the safety,tolerability and pharmacokinetics (PK) of LP-108, a BCL-2 inhibitor, combined with azacitidine, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RP2D), and to assess the preliminary efficacy of this combination.

Description:

This Phase 1 study will look at different doses and different treatment schedules in order to better understand the effects of the combined regimens on the newly diagnosed or refractory/relapsed adult participants with AML ,MDS or CMML. The procedures include screening for eligibility, study treatments, and blood & bone marrow tests. All the safety events will be record, pharmacokinetic parameters (Tmax, Cmax,T1/2, AUC et al.) will be calculated, response and survival will be assess during the study. Participants will be treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 198
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject must has a diagnosis of one of the following: relapsed or refractory (R/R) or untreated ineligible for treatment with a standard induction chemotherapy acute myeloid leukemia (AML) ; R/R myelodysplastic syndrome(MDS) or untreated MDS with excess blasts defined as = 5% blasts in either bone marrow or blood or with high risk (high and very high-risk groups according to IPSS-R) ;CMML-1 or 2 by WHO, no requirements for prior therapy.

• ECOG performance status = 2.

• Estimated survival = 12 weeks.

• Baseline white blood cell count (WBC) = 25 x 109/L.

• Subject must has adequate organ function as defined below: Aspartate transaminase (AST) and alanine transaminase (ALT)=3 x ULN; Bilirubin =1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin); adequate renal function as demonstrated by a creatinine clearance =1.5 x ULN ; calculated by the Cockcroft Gault formula; APTT = 1.5 x ULN, INR = 1.5 x ULN.

• Prior treatment-related toxicities must be grade 1 or baseline except for alopecia.

• If subject is sexually active, he/she must agree to carry out birth control throughout the study and 90 days after the last dose of LP-108. Subject must agree to have a negative serum ß-HCG test result within 7 days prior to study drug.

• Subject must voluntarily sign and date an informed consent.

Exclusion Criteria:

• Subject is allergic to LP-108, Azacitidine or excipients, or with poor tolerance to Azacitidine.

• Subject has received prior therapy with a BH3 mimetic.

• Subject has acute promyelocytic leukemia.

• Subject has t(9;22) karyotype abnormality or positive BCR/ABL1 fusion gene.

• Subject has known and active CNS involvement.

• Subject has myeloid sarcoma but no bone marrow involvement.

• Subject has Acute unidentified leukemia.

• Subject has treatment related MDS or AML.

• Subject has AML/MDS/CMML with myelofibrosis = grade 2.

• Subject has received allogeneic Hematopoietic Stem Cell Transplantation (HSCT) or autologous HSCT within 3 months prior to the first dose of study drug.

• Subject must be at least 4 weeks from antitumor therapy, major surgery, radiation therapy, or participation in other investigational trials.

• Subject has received a strong and/or moderate CYP3A inhibitor or inducer, P-gp inhibitor or CYP2C8 substrate within 14 days prior to the initiation of study treatment.

• Subject has received drugs with a potential to cause prolonged QT intervals or torsade de pointes.

• Administration or consumption of any of the following within 3 days prior to the first dose of study drug: Grapefruit or grapefruit products; Seville oranges (including marmalade containing Seville oranges); Star fruit.

• Subject has known malignancy within 3 years prior to the first dose of study drug, with the exception of: Adequately treated basal skin cancers, in situ carcinoma of the cervix uteri or breast, localized squamous cell carcinoma.

• Subject has serious and/or uncontrolled systemic diseases, in the opinion of the investigator, the subject is inappropriate for enrollment into this study (serious active infection with grade = 2(based on CTCAE), high blood pressure that cannot be controlled by medication, diabetes, unstable angina, congestive heart failure, Respiratory diseases requiring continuous oxygen intake, severe vascular embolism, uncontrolled massive bleeding or bleeding from vital organs, severe liver, kidney or metabolic diseases, such as cirrhosis, kidney failure, etc.).

• Subject has myocardial infarction or stroke within 6 months prior to the first dose of study drug.

• Subject has a cardiac history including the following: History of CHF requiring treatment or Ejection Fraction <50% or a cardiovascular disability status of New York Heart Association.

• Subject has uncontrolled and/or active systemic infection (viral, bacterial or fungal).

• Subject has difficulty to swallow pills or has conditions that affect drug absorption or pharmacokinetics.

• Strong and/or moderate CYP3A inhibitor or inducer and CYP2C8 substrate cannot be discontinued during the study.

• Vaccination with live, attenuated vaccines =4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study or 4 weeks after the last dose of study drug.

• Subject has an autoimmune disease that requires immunosuppressive therapy In the opinion of the investigator, the subject is inappropriate for enrollment into this study.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Chronic Myelomonocytic Leukemia
• Leukemia
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndromes

Intervention

Drug:
• LP-108
Oral administration for 21 or 28 days on a 28-day cycle
• Azacitidine
Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Nanchang University	Nanchang
China	First Affiliated Hospital of Soochow University	Suzhou
China	Affiliated Tumor Hospital of Zhengzhou University, Henan Cancer Hospital	Zhengzhou

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou Lupeng Pharmaceutical Company LTD.

Country where clinical trial is conducted

China, 

References & Publications (3)

Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Gr — View Citation

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD. Diagnosi — View Citation

Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF; MD — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose(MTD)	Standard phase I 3+3 design. The first 3 subjects will be assigned to dose level 1 cohort. If none of the first three subjects experiences DLT, escalation to dose level 2 cohort is permitted. If one of the first three subjects' experiences DLT, a total of six subjects will be required in that dose cohort, and escalation will only be permitted if five of six subjects do not experience DLT. If more than one DLT is observed in the dose level 2 cohort, this will be determined to be the maximally administered dose, and three more subjects will be enrolled in the dose level 1 cohort if only three were previously treated at that dose. Escalation from dose level 2 to level 3 cohort will be with the same method as before. The MTD will be the cohort in which =1/6 subjects have dose limiting toxicity at the dose prior to the maximally administered dose. If the dose level 3 cohort has =1/6 subjects with a DLT, the MTD will not have been reached.	Up to 42 days after initial dose of study drug at the designated cohort dose.
Primary	Recommended Phase 2 Dose(RP2D)	RP2D will be determined using available safety and pharmacokinetics data upon completion of the dose escalation phase.	Up to 1.5 years
Primary	Incidence of AEs	Type, frequency and severity of AEs, relationship of AEs to study treatment	From first dose of study drug to 28 days after last dose of study drug
Primary	Incidence of clinically significant changes in clinical laboratory results	Clinically significant changes in hematology, chemistry, coagulation and urinalysis tests results.	From first dose of study drug to 28 days after last dose of study drug
Primary	Cmax of LP-108	Maximum plasma concentration (Cmax) of LP-108.	Up to 24 hours post dose
Primary	Tmax of LP-108	Time to maximum plasma concentration (Tmax) of LP-108.	Up to 24 hours post dose
Primary	t1/2 of LP-108	The terminal elimination half-life (t1/2).	Up to 24 hours post dose
Primary	AUC0-t of LP-108	Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration of LP-108.	Up to 24 hours post dose
Primary	CL/F of LP-108	Apparent clearance (CL/F) of LP-108.	Up to 24 hours post dose
Primary	Vd/F of LP-108	Apparent volume of distribution of LP-108.	Up to 24 hours post dose
Secondary	Objective Response Rate (ORR)	Response criteria follows the 2017 European Leukemia Net (ELN) recommendations for AML( CR, CRi, PR) , the International Working Group (IWG) response criteria for MDS(CR, PR, marrow CR, HI), the international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults(CR, PR, Marrow response, Clinical benefit).	Measured from Cycle 1 Day 1 to 28 days after last dose of study drug, and assessed up to 24 months.
Secondary	Progression-Free Survival(PFS) (only for MDS or CMML)	PFS is defined as the number of days from the date of the first dose of study drug to the date of earliest disease progression or death.	Measured from the date of first dose of study drug to the date of earliest disease progression or death or last visit, and assessed up to 24 months.
Secondary	Time to Response(TTR)	TTR is defined as the number of days from the date of the first dose of study drug to the date of earliest response.	Measured from the date of the first dose of study drug to the date of earliest response, and assessed up to 6 months.
Secondary	Duration of Response(DOR)	DOR is defined as the number of days from the date of the first remission to the date of earliest disease progression or death.	Measured from the date of the first remission to the date of earliest disease progression or death, and assessed up to 24 months.
Secondary	DOCR (only for CR/CRi participants)	DOCR is defined as the number of days from the date of the first CR/CRi to the date of earliest disease progression or death.	Measured from the date of the first CR/CRi to the date of earliest disease progression or death, and assessed up to 24 months.
Secondary	Event-free Survival (EFS)	EFS is defined as the number of days from the date of first dose to the date of earliest evidence of disease progression/relapse, or initiation of new non-protocol-specified antitumor therapy without documented progression, or death.	Measured from the date of first dose to the date of earliest evidence of disease progression, initiation of new non-protocol-specified antitumor therapy without documented progression, death, and for up to 5 years after the last subject is enrolled.
Secondary	OS	OS is defined as the number of days from the date of first dose to the date of death.	Measured from the date of date of first dose to the date of death or last visit, and for up to 5 years after the last subject is enrolled.